Healthtech/News/ Snoop Dogg’s VC makes first investment in continental Europe The rapper’s VC firm Casa Verde invests in Lisbon-based AceCann. By Tim Smith in Barcelona 12 October 2021 Casa Verde Casa Verde \Healthtech Moka.care raises €15m Series A for its employee mental health platform By Amy Lewin 24 May 2022 Healthtech/News/ Snoop Dogg’s VC makes first investment in continental Europe The rapper’s VC firm Casa Verde invests in Lisbon-based AceCann. By Tim Smith in Barcelona 12 October 2021 There are few people in this world who know more about cannabis than US rap legend Snoop Dogg, and now the weed enthusiast-cum-entrepreneur is bringing his herbal expertise to Europe. The Doggfather, otherwise known as Calvin Broadus, is cofounder of LA-based VC fund Casa Verde, and the firm is today announcing its first investment into continental Europe (their first investment in Europe more widely was into Oxford Cannabinoid Technologies in 2018), leading a $15m round into Lisbon-based AceCann. Founded in 2019, AceCann is a medical cannabis company that’s focused on the cultivation and extraction of organic medical cannabis. The startup will use the funding to develop a “state-of-the-art” production facility in Vendas Novas, an hour outside of Lisbon. Speaking to Sifted ahead of the announcement, AceCann chief executive Pedro Gomes said that Snoop Dogg and Casa Verde’s involvement represents a huge show of confidence in the startup. “Having Casa Verde on board, with their track record in the US, and being their first investment in Europe, it’s definitely a stamp of quality for us,” he says. Taking it inside Gomes describes how many early investors into European cannabis, many of them from Canada, focused on Portugal due to its low labour costs and sunny climate, but AceCann will now be using a fully indoor production process. The reason for this is the high degree of consistency required for medical cannabis. “In the medical market you need to be very accurate in the way you produce and you need to make sure that you’re consistent in your production,” he explains. “We pivoted this to do this in an indoor facility so that’s already something different to most other European projects.” Pedro Gomes, AceCann chief executive The new facility will provide for 3,500m² of cannabis production, which will be expandable as the market grows. Gomes predicts that by 2024 AceCann’s new facility could produce up to €15-20m in annual sales. The next episode While North America has led the way in legalising the use of medical and recreational cannabis, Europe is catching up, particularly when it comes to regulating medical usage. The market for medical cannabis in Europe is predicted to reach $3.4bn by 2024, and it’s proving a big lure for investors. “As legalisation sweeps across Europe, we foresee a rapid and exponential rise in demand for high-quality cannabis flower and extracts,” says Yonatan Meyer, partner at Casa Verde. Source: Cannigma But while many countries are starting to allow medical cannabis use, the regulatory picture is extremely patchwork, says Gomes. Germany, he explains, is one of the only European countries that will reimburse the purchase of a prescribed course of medical cannabis, greatly inflating the relative size of the market there. “It’s a big difference when you’re talking about the uptake in market,” he says. “You need the people to be able to pay for their medicine. In Portugal, at €10 a gram, it’s slightly difficult for a Portuguese person to be able to do a continuous treatment with medical cannabis.” Gomes does however believe that while countries are moving at different paces, as more of them open up to medical cannabis there will be a “cascade” of countries treating medical cannabis like any other medicine. With opportunity, of course, comes competition, and in Portugal alone there are 16 startups with cultivation licences competing to stock Europe’s medicine cabinets with cannabis. Gomes is hoping that AceCann’s indoor production process will translate into a higher quality and more consistent product than its rivals. And with Snoop Dogg and Casa Verde’s backing, the startup has certainly got its nose in front of the pack when it comes to high-profile backers. Tim Smith is Sifted’s Iberia correspondent. He tweets from @timmpsmith Correction note: on 12th October 2021 Sifted amended a chart, sourced from Cannigma, showing countries that allow use of medical cannabis. The original chart stated that medical cannabis is legal in Russia. It is not legal in Russia and the new chart reflects this. Related Articles We want diverse founders to access the Future Fund By John Glen Click here to read more Lessons learned: When not-perfect is good enough Sponsored by Google For Startups Click here to read more Put a ring on it: Employers keen to help monitor employees’ health By Kit Gillet in Bucharest Click here to read more Ada Health raises $90m, plans further US expansion By Amy Lewin Click here to read more Most Read 1 \Startup Life Tech company layoffs in Europe: the list 2 \Consumer Gorillas halves its headcount at HQ 3 \Startup Life From Revolut to Back Market: the European startups still hiring despite the tech downturn 4 \Venture Capital Ranking: UK tech startups to watch in 2022 5 \Startup Life Why startup founders should always pay themselves a fair market salary 2 Join the conversation Subscribe newest oldest Notify of new follow-up comments new replies to my comments LithuanianMedicinal cannabis is very illegal in Lithuania, they legalized synthetic cannabinoids (spice, sativex, syndros and all that crap) but cannabis plant and natural extracts are not legalized, they put even for cancer patients in jail for this plant, so fix your image Klāvs VegnersHow yall get a writer who puts in “enthusiast-cum-entrepeneur”? How can you expect anyone to keep reading the article? 😂
Lessons learned: When not-perfect is good enough Sponsored by Google For Startups Click here to read more
Put a ring on it: Employers keen to help monitor employees’ health By Kit Gillet in Bucharest Click here to read more